Aridis Pharmaceuticals

General Information


We are a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. mAbs represent a fundamentally new treatment approach in the infectious disease market and are designed to overcome key issues associated with current therapies, including drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation between treatment alternatives.

Employees: 25
Founded: 2003
Contact Information
Address 5941 Optical Court, San Jose, CA 95138, US
Phone Number (408) 385-1742
Web Address
View Prospectus: Aridis Pharmaceuticals
Financial Information
Market Cap $102.57mil
Revenues $0 mil (last 12 months)
Net Income $-27.6 mil (last 12 months)
IPO Profile
Symbol ARDS
Exchange NASDAQ
Shares (millions): 2.0
Price range $13.00 - $13.00
Est. $ Volume $26.0 mil
Manager / Joint Managers Cantor
CO-Managers Maxim Group/ Northland Capital Markets
Expected To Trade: 8/14/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change